Across 134 first-hand reports, people mentioned a side effect 12 times (about 9 per 100 reports). The most common: hppd, psychosis, anxiety. User reports show what people notice — they can't tell you whether LSD is safe for you.
“Visualizing electric fields was effortless...I realized I had taken way too much for what I was trying to do. It was hard to focus, certain muscles were tightening up, I was sweating more.”
“Two or three tabs later and some really strange trips, nobody I used to know can recognize me since I’ve changed so much for the better.”
“LSD (I microdose a few times a week, started this recently, 1-2 months ago. Seems to help with the social anxiety)...I would honestly get off the LSD if it's not working yet. Hallucinogens can cause psychosis.”
“I began microdosing about two weeks ago and that's when things started to change...social anxiety, ADHD, and any form of existential depression disappeared”
“I did a lot of acid to try and have an 'ego death'...I lost it for a while. I became unsure of everything”
“microdosing LSD has been... odd. I really feel like everyone around me is running around like a chicken with their head cut off. It can be depressing sometimes, and I really don't see how it can be considered "nootropic"”
Conclusion: Nearly a third of the articles reported that no participants reported lasting adverse effects. Our analyses suggest that psychedelics reduce negative mood, and have potential efficacy in other mental disorders, such as substance-use disorders and PTSD.
Conclusion: In this systematic review and meta-analysis, classic psychedelics were generally well tolerated in clinical or research settings according to the existing literature, although SAEs did occur. These results provide estimates of common AE frequencies and indicate that certain catastrophic events reported in recreational or nonclinical contexts have yet to be reported in contemporary trial participants. Careful, ongoing, and improved pharmacovigilance is required to understand the risk and benefit profiles of these substances and to communicate such risks to prospective study participants and the
Conclusion: Stroke genetic risk scores were predictive of ischaemic stroke independent of clinical risk factors in 52,600 clinical-trial participants with cardiometabolic disease. Our results provide insights to inform biology, reveal potential drug targets and derive genetic risk prediction tools across ancestries.